Traynor Capital Management, Inc. Gilead Sciences, Inc. Transaction History

Traynor Capital Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 01, 2019	SELL	$62.51 - $69.0 $388,749 - $429,111	-6,219 Closed	0 $0
Q2 2019 Jul 26, 2019	SELL	$61.87 - $69.38 $127,019 - $142,437	-2,053 Reduced 24.82%	6,219 $421,000
Q1 2019 Apr 12, 2019	SELL	$62.53 - $70.05 $273,318 - $306,188	-4,371 Reduced 34.57%	8,272 $537,000
Q4 2018 Jan 24, 2019	BUY	$60.54 - $79.0 $6,235 - $8,137	103 Added 0.82%	12,643 $790,000
Q3 2018 Oct 24, 2018	SELL	$71.28 - $78.92 $120,677 - $133,611	-1,693 Reduced 11.89%	12,540 $968,000
Q2 2018 Aug 03, 2018	SELL	$64.88 - $75.68 $701,482 - $818,252	-10,812 Reduced 43.17%	14,233 $1.01 Million
Q1 2018 May 01, 2018	BUY	$72.84 - $88.8 $46,908 - $57,187	644 Added 2.64%	25,045 $1.89 Million
Q4 2017 Feb 01, 2018	SELL	$71.15 - $83.52 $276,702 - $324,809	-3,889 Reduced 13.75%	24,401 $1.75 Million
Q3 2017 Oct 27, 2017	BUY	$72.11 - $85.47 $2.04 Million - $2.42 Million	28,290	28,290 $2.29 Million

1,893

1.02B

12M

8.96M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $111B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Traynor Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Traynor Capital Management, Inc. with notifications on news.